Compare AbbVie Inc (ABBV) vs Sea Limited (SE) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Sea Limited (SE) trades at $104.23, up 0.9% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong revenue growth, with 2025 revenue reaching $22.94 billion and net income of $1.58 billion, though recent quarters have mixed earnings performance. Analyst consensus remains strongly positive with a $131 price target, supported by improving cash flow trends and expanding profitability.

The outlook for SE is favorable given robust growth in its digital ecosystem and positive analyst sentiment, but risks include competitive pressures in Southeast Asian markets and potential volatility from earnings misses. Investors should weigh the high P/E ratio of 41.34 against the company's accelerating top-line expansion and margin improvements.